Targeted Auger Electron Radiotherapy of Malignancies

Monoclonal Antibody and Peptide-Targeted Radiotherapy of Cancer

Volumn , Issue , 2010, Pages 289-348

  Reilly, Raymond M ^a,b   Kassis, Amin ^c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Auger electron emitting radionuclides for radiolabeling monoclonal antibodies (mAbs), or peptides; Molecular targets for auger electron radiotherapy of cancer; Targeted auger electron radiotherapy of malignancies

Indexed keywords

EID: 80052623580     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470613214.ch9     Document Type: Chapter

References (247)

1. Auger P. Sur les rayons β secondaires produits dans un gaz par des rayons X. Comptes Rendues Hebdomadaires des Seances de l'Académie des Sciences 1925;180:65-68.
2. Cole A. Absorption of 20-eV to 50,000-eV electron beams in air and plastic. Radiat Res 1969;38:7-33.
3. Kassis AI. The amazing world of Auger electrons. Int J Radiat Biol 2004;80:789-803.
4. 35S: theory and application to a cellular model. Radiat Res 1980;84:407-425.
5. 125IUdR in mammalian cells: implications of localized energy deposition by Auger processes. Radiat Res 1987;109:78-89.
6. 125I in mammalian cells. Radiat Res 1987;111:305-318.
7. 125. J Chem Phys 1963;38:2930-2934.
8. Kassis AI, Adelstein SJ, Haydock C, Sastry KSR, McElvany KD, Welch MJ. Lethality of Auger electrons from the decay of bromine-77 in the DNA of mammalian cells. Radiat Res 1982;90:362-373.
9. 125I]iodo-2'-deoxyuridine. Radiat Res 1989;118:532-544.
10. Kassis AI, Makrigiorgos GM, Adelstein SJ. Dosimetric considerations and therapeutic potential of Auger electron emitters. In: Adelstein SJ, Kassis AI, Burt RW, editors. Frontiers in Nuclear Medicine: Dosimetry of Administered Radionuclides, Proceedings of Symposium, 1989. American College of Nuclear Physicians, Washington, DC, 1990, pp. 257-274.
11. 125I and 3H: nuclear versus cytoplasmic radiation effects in murine L1210 leukaemia. Int J Radiat Biol 1975; 28:225-241.
12. Kassis AI, Adelstein SJ, Haydock C, Sastry KSR. Thallium-201: an experimental and a theoretical radiobiological approach to dosimetry. J Nucl Med. 1983;24:1164-1175.
13. Kassis AI, Sastry KSR, Adelstein SJ. Intracellular distribution and radiotoxicity of chromium-51 in mammalian cells: Auger-electron dosimetry. J Nucl Med 1985; 26:59-67.
14. 125I-bovine serum albumin. Radiat Res 1993; 133: 182-186.
15. Warters RL, Hofer KG, Harris CR, Smith JM. Radionuclide toxicity in cultured mammalian cells: elucidation of the primary site of radiation damage. Curr Top Radiat Res Q 1977;12:389-407.
16. Kassis AI, Howell RW, Sastry KSR, Adelstein SJ. Positional effects of Auger decays in mammalian cells in culture. In: Baverstock KF, Charlton DE, editors. DNA Damage by Auger Emitters. Taylor and Francis, London, 1988, pp. 1-13.
17. 125I-labeled DNA-binding compound that induces double-stranded DNA breaks. Cancer Res 1979;39: 3244-3247.
18. 125I--labeled DNA intercalator in mammalian cells. Radiat Res 1989;118:283-294.
19. HowellRW, Kassis AI, Adelstein SJ, et al. Radiotoxicity of platinum-195m-labeled transplatinum (II) in mammalian cells. Radiat Res 1994;140:55-62.
20. Bloomer WD, McLaughlin WH, Weichselbaum RR, et al. Iodine-125-labelled tamoxifen is differentially cytotoxic to cells containing oestrogen receptors. Int J Radiat Biol 1980;38:197-202.
21. Bloomer WD, McLaughlin WH, Milius RA, Weichselbaum RR, Adelstein SJ. Estrogen receptor-mediated cytotoxicity using iodine-125. J Cell Biochem 1983;21:39-45.
22. 125I]iodoestradiol in cultured MCF-7 human breast cancer cells. J Natl Cancer Inst 1989;81:437-440.
23. 125I]iodovinyl-11β-methoxyestradiol in MCF-7 human breast cancer cells. J Steroid Biochem Mol Biol 1991;39:729-734.
24. 123I] iodovinyl-11β-methoxyestradiol and CHO-ER cells. In: Howell RW, Narra VR, Sastry KSR, Rao DV, editors. Biophysical aspects of Auger processes, American Association of Physicists in Medicine, Symposium Series No 8. American Institute of Physics, Woodbury, NY, 1992, pp. 352-371.
25. 125I decay in the DNA double strand break repair deficient mutant cell line, xrs-5. Int J Radiat Biol 1992;62:613-618.
26. DeSombre ER, Hughes A, Landel CC, Greene G, Hanson R, Schwartz JL. Cellular and subcellular studies of the radiation effects of Auger electron-emitting estrogens. Acta Oncol 1996;35:833-840.
27. Kearney T, Hughes A, Hanson RN, DeSombre ER. Radiotoxicity of Auger electronemitting estrogens in MCF-7 spheroids: a potential treatment for estrogen receptorpositive tumors. Radiat Res 1999;151:570-579.
28. 125I-estrogen decays in estrogen receptor-expressing MCF-7 human breast cancer cells. Radiat Res 2001;155:328-334.
29. 125I-oestrogen decay in nonoestrogen receptor-expressing human breast cancer cells, MDA-231 and oestrogen receptor-expressing MCF-7 cells. Int J Radiat Biol 2001;77:955-962.
30. 125I]iodoHoechst 33342: contribution of scavengeable effects. Int J Radiat Biol 1999;75:1579-1587.
31. 125I-labelled DNA ligand. Acta Oncol 2000;39:681-685.
32. Sedelnikova OA, Panyutin IG, Thierry AR, Neumann RD. Radiotoxicity of iodine-125-labeled oligodeoxyribonucleotides in mammalian cells. J Nucl Med 1998;39: 1412-1418.
33. Yasui LS, Chen K, Wang K, et al. Using Hoechst 33342 to target radioactivity to the cell nucleus. Radiat Res 2007;167:167-175.
34. Sastry KSR, RaoDV. Dosimetry of lowenergy electrons. In: RaoDV, Chandra R, Graham MC, editors. Physics of Nuclear Medicine: Recent Advances. American Institute of Physics, Woodbury, NY, 1984, pp. 169-208.
35. Pomplun E, Booz J, Charlton DE. A Monte Carlo simulation of Auger cascades. Radiat Res 1987;111:533-552.
36. 125I. Int J Radiat Biol 1988;53:353-365.
37. Kassis AI, Harapanhalli RS, Adelstein SJ. Comparison of strand breaks in plasmid DNA after positional changes of Auger electron-emitting iodine-125. Radiat Res 1999; 151:167-176.
38. Kassis AI, Harapanhalli RS, Adelstein SJ. Strand breaks in plasmid DNA after positional changes of Auger electron-emitting iodine-125: direct compared to indirect effects. Radiat Res 1999;152:530-538.
39. 125I-Hoechst. Radiat Res 2006;166:333-344.
40. 125I--decay in a synthetic oligodeoxynucleotide: fragment distribution and evaluation of DMSO protection effect. Acta Oncol 1996;35:803-808.
41. 125I incorporated into a triplex-forming oligonucleotide correlates with geometry of the triplex. Nucleic Acids Res 1997;25:883-887.
42. Walicka MA, Adelstein SJ, Kassis AI. Indirect mechanisms contribute to biological effects produced by decay of DNA-incorporated iodine-125 in mammalian cells in vitro: double-strand breaks. Radiat Res 1998;149:134-141.
43. 125I decay: effects of DNA conformation. Acta Oncol 2000;39:721-726.
44. 125I induces more than one double-strand break per decay in mammalian cells. Radiat Res 2005;163:369-373.
45. Balagurumoorthy P, Chen K, Adelstein SJ, Kassis AI. Auger electron-induced doublestrand breaks depend on DNA topology. Radiat Res 2008;170(1): 70-82.
46. Nagasawa H, Little JB. Induction of sister chromatid exchanges by extremely low doses of α-particles. Cancer Res. 1992;52:6394-6396.
47. Hickman AW, Jaramillo RJ, Lechner JF, Johnson NF. α-Particle-induced p53 protein expression in a rat lung epithelial cell strain. Cancer Res 1994;54:5797-5800.
48. Azzam EI, de Toledo SM, Gooding T, Little JB. Intercellular communication is involved in the bystander regulation of gene expression in human cells exposed to very lowfluences of alpha particles. Radiat Res 1998;150:497-504.
49. Xue LY, Butler NJ, MakrigiorgosGM, Adelstein SJ, Kassis AI. Bystander effect produced by radiolabeled tumor cells in vivo. Proc Natl Acad Sci USA 2002;99:13765-13770.
50. Barcellos-Hoff MH, Chaudhry MA, De Veaux L, et al. Meeting report: radiation-induced genomic instability and bystander effects; implications for evolutionary biology, report on an international workshop on radiation-induced low-dose effects held at McMaster University in Hamilton, Ontario, Canada, October 28-November 1, 2004. Radiat Res 2005;163:473-476.
51. Kishikawa H, Wang K, Adelstein SJ, Kassis AI. Inhibitory and stimulatory bystander effects are differentially induced by iodine-125 and iodine-123. Radiat Res 2006;165:688-694.
52. 125I. Micron 2002;33:127-132.
53. Boyd M, Ross SC, Dorrens J, et al. Radiation-induced biologic bystander effect elicited in vitro by targeted radiopharmaceuticals labeled with α-, β-, and Auger electron-emitting radionuclides. J Nucl Med 2006;47:1007-1015.
54. O'Donoghue JA, Wheldon TE. Targeted radiotherapy using Auger electron emitters. Phys Med Biol 1996;41:1973-1992.
55. Howell RW. Radiation spectra for Auger-electron emitting radionuclides: Report no. 2 of AAPM Nuclear Medicine Task group No. 6. Med Phys 1992;19:1371-1383.
56. Govindan SV, Goldenberg DM, Elsamra SE, Griffiths GL, Ong GL, BrechbielMW, et al. Radionuclides linked to a CD74 antibody as therapeutic agents for B-cell lymphoma: comparison of Auger electron emitters with β-particle emitters. J Nucl Med 2000; 41:2089-2097.
57. Bernhardt P, Forssell-Aronsson E, Jacobsson L, Skamemark G. Low-energy electronemitters for targeted radiotherapy of small tumours. Acta Oncologica 2001;40:602-608.
58. Goddu SM, Howell RW, Rao DV. Cellular dosimetry: absorbed fractions for monoenergetic electron and alpha particle sources and S-values for radionuclides uniformly distributed in different cell compartments. J Nucl Med 1994;35:303-316.
59. Richter MP, Horvick D. Principles of Radiation Oncology. In: Calabresi P, Schein PS, editors. Medical Oncology: Basic Principles and Clinical Management of Cancer, 2nd edition. McGraw-Hill, Inc., Toronto, 1993, pp. 253-262.
60. 90Y-labelled monoclonal antibodies for ovarian cancer: pharmacokinetics and normal tissue dosimetry. Int J Cancer 1988;3 (Suppl): 71-76.
61. 90Y activity needed to achieve certain tumor radiation doses in colorectal cancer patients. Cancer Res 1990;50 (Suppl): 1029s-1030s.
62. Reilly RM. Biomolecules as targeting vehicles for in situ radiotherapy of malignancies. In: Knaeblein J, Mueller R, editors. Modern Biopharmaceuticals: Design, Development and Optimization. Wiley-VCH, Weinheim, Germany, 2005; pp. 497-526.
63. Goddu SM, Rao DV, Howell RW. Multicellular dosimetry for micrometastases: dependence of self-dose versus cross-dose to cell nuclei on type and energy of radiation and subcellular distribution of radionuclides. J Nucl Med 1994;35:521-530.
64. 125I-iododeoxyuridine as prototype for radionuclide therapy with Auger emitters. Nature 1977;265:620-662.
65. 123I]iodo-2'-deoxyuridine in the radiotherapy of an early ascites tumor model. Int J Radiat Oncol Biol Phys 1991;21:1541-1551.
66. 125I]iodo-2'-deoxyuridine. Acta Oncol 2000;39:731-737.
67. 125I]iodo-2'-deoxyuridine and methotrexate in the treatment of advanced neoplastic meningitis. Int J Radiat Biol 2004;80:941-946.
68. 125IUdR. Int J Radiat Biol 2008;84 (12):1123-1129.
69. Guillermmet-Guibert J, Lahlou H, Cordelier P, Bousquet C, Pyronnet S, Susini C. Physiology of somatostatin receptors. J Endocrinol Invest 2005;28 (11 Suppl): 5-9.
70. Csaba Z, Dournand P. Cellular biology of somatostatin receptors. Neuropeptides 2001;35:1-23.
71. Florio T. Molecular mechanisms of the antiproliferative activity of somatostatin receptors (SSTRs) in neuroendocrine tumors. Frontiers in Bioscience 2008;13:822-840.
72. Reubi JC, Schar J-C, Waser B, Wenger S, Heppeler A, Schmitt JS, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 2000;27:273-282.
73. 90Y-DOTA-lanreotide: results and implications of the MAURITIUS trial Semin Nucl Med 2002;32:148-155.
74. Kwekkeboom DJ, Krenning EP. Somatostatin receptor imaging. Semin Nucl Med 2002;32:84-91.
75. Lamberts SWJ, Reubi J-C, Krenning EP. The role of somatostatin analogs in the control of tumor growth. Semin Oncol 1994;21:61-64.
76. 3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993;20:716-731.
77. Van Essen M, Krenning EP, de Jong M, Valkema R, Kwekkeboom D. Peptide receptor radionuclide therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours. Acta Oncologica 2007;46:723-34.
78. Maecke HR, Hofmann M, Haberkorn U. 68Ga-labeled peptides in tumor imaging J Nucl Med 2005;46:172S-178S.
79. Smith-Jones PM, Bischof C, Leimer M, Gludovacz D, Angelberger P, et al. DOTAlanreotide: a novel somatostatin analog for tumor diagnosis and therapy. Endocrinol 1999;140:5136-5148.
80. Reubi JC, Schaer JC, Waser B, Mengod G. Expression and localization of somatostatin receptor SSTR1, SSTR2, and SSTR3 messenger RNAs in primary human tumors using in situ hybridization. Cancer Res 1994;54:3455-3459.
81. Reubi JC,Waser B, Schaer JC, Laissue JA. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtypeselective ligands. Eur J Nucl Med Mol Imaging 2001;28:836-846.
82. Reubi JC, Waser B, Foekens JA, Klijn JGM, Lamberts SWJ, Laissue J. Somatostatin receptor incidence and distribution in breast cancer using receptor autoradiography: relationship to EGF receptors. Int J Cancer 1990;46:416-420.
83. Reubi JC,Waser B. Concomitant expression of several peptide receptors in neuroendcrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging 2003;30:781-793.
84. Oomen SPMA, Hofland LJ, van Hagen PM, Lamberts SWJ, Touw IP. Somatostatin receptors in the hematopoietic system. Eur J Endocrinol 2000;143:S9-S14.
85. Aguila MC, Rodriguez AM, Aguila-Mansilla HN, Lee WT. Somatostatin antisense oligodeoxynucleotide-mediated stimulation of lymphocyte proliferation in culture. Endocrinol 1996;137:1585-1590.
86. Duncan JR, Stephenson MT, Wu HP, Anderson CJ. Indium-111-diethylenetriaminepentaacetic acid-octreotide is delivered in vivo to pancreatic, tumor cell, renal, and hepatic lysosomes. Cancer Res 1997;57:659-671.
87. Gotthardt M, van Eerd-Vismale J, Oyen WJ, de Jong M, Zhang H, Rolleman E, et al. Indication for different mechanisms of kidney uptake of radiolabeled peptides. J Nucl Med 2007;48:596-601.
88. Duncan JR, Welch MJ. Intracellular metabolism of indium-111-DTPA labeled receptor targeted proteins. J Nucl Med 1993;34:1728-1738.
89. 111In-DTPA--lysine as the primary metabolic and excretory product. Nucl Med Biol 1994;21:1023-1034.
90. Nouel D, Gaudriault G, Houle M, Reisine T, Vincent J-P, Mazella J, et al. Differential internalization of somatostatin in COS-7 cells transfected with SST1 and SST2 receptor subtypes: a confocal microscopic study using novel fluorescent somatostatin derivatives. Endocrinol 1997;138:296-306.
91. Cescato R, Schutlz S, Waser B, Eltschinger V, Rivier JE, et al. Internalization of sst2, sst3, and sst5 receptors: effects of somatostatin agonists and antagonists. J Nucl Med 2006;47:502-511.
92. 1-octreotide. J Nucl Med 1996;37: 2002-2006.
93. 3]octreotide: peptides for somatostatin receptor-targeted scintigraphy and radionuclide therapy. Nucl Med Commun 1998;19:283-288.
94. Wang M, Caruano AL, Lewis MR, Meyer LA, VanderWaal RP, Anderson CJ. Subcellular localization of radiolabeled somatostatin analogues: implications for targeted radiotherapy of cancer. Cancer Res 2003;63:6864-6869.
95. Eiblmaier M, Andrews R, LaForest R, Rogers BE, Anderson CJ. Nuclear uptake and dosimetry of 64Cu-labeled chelator-somatostatin conjugates in an SSTr2-transfected human tumor cell line. J Nucl Med 2007;48:1390-1396.
96. Hornick CA, Anthony CT, Hughey S, Gebhardt BM, Espenan GD, Woltering EA. Progressive nuclear translocation of somatostatin analogs. J Nucl Med 2000; 41:1256-1263.
97. 111In]DTPA-hEGF. Nucl Med Biol 2007;34: 887-896.
98. 111In-DTPA human epidermal growth factor. J Nucl Med 2007;48:1562-1570.
99. 111In- labeled EGF is selectively radiotoxic to human breast cancer cells overexpressing EGFR. J Nucl Med 2000;41:429-438.
100. Rakowicz-Szulczynska EM, Rodeck U, Herlyn M, Koprowski H. Chromatin binding of epidermal growth factor, nerve growth factor, and platelet-derived growth factor in cells bearing the appropriate surface receptors. Proc Natl Acad Sci USA 1986; 83:3728-3732.
101. 1]-octreotide in patients with neuroendocrine tumours. J Nucl Med 2000;41:1514-1518.
102. Likinius A, Ohrvall U,Westlin J-E, Oberg K, Janson ET. In vivo cellular distribution and endocytosis of the somatostatin receptor-ligand complex. Acta Oncologica 1999; 38:383-387.
103. 0]octreotide. J Nucl Med 2003;44: 98-104.
104. Slooter GD, BreemanWAP, Marquet RL, Krenning EP, Van Eijck CHJ. Anti-proliferative effect of radiolabelled octreotide in a metastasis model in rat liver. Int J Cancer 1999; 81:767-771.
105. 111In-labelled somatostatin analogues in a rat tumour model: somatostatin receptor status and effects of peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging 2005;32: 1288-1295.
106. 3]-octreotide radionuclide therapy in a transplantable rat tumor model is dependent on tumor size. J Nucl Med 2001;42:1841-1846.
107. 1]-octreotide. A case history. Ann NY Acad Sci 1994;733:496-506.
108. 1-octreotide in midgut carcinoid syndrome. J Nucl Med 1996;37:1519-1521.
109. 1]-octreotide in patients with neuroendocrine tumors. Acta Oncologica 1999;38:373-377.
110. 111In-octreotide therapy in patients with disseminated neuroendocrine tumours. Nucl Med Commun 2000;21:97-102.
111. 111In-DTPA 0]octreotide: the Rotterdam experience. Semin Nucl Med 2002;32(2): 110-122.
112. Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 1991;21:109-122.
113. Anthony LB, Woltering EA, Espenan GD, Cronin MD, Maloney TJ, McCarthy KE. Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies. Semin Nucl Med 2002;32:123-132.
114. Delpassand ES, Sims-Mourtada J, Saso H, Azhdarinia A, Ashoori F, Torabi F, et al. Safety and efficacy of radionuclide therapy with high-activity In-111 pentetreotide in patients with progressive neuroendocrine tumors. Cancer Biother Radiopharm 2008; 23:292-300.
115. Nguyen C, Faraggi M, Giraudet A-L, de Labriolle-Vaylet C, Aparicio T, Rouzet F, et al. Long-term efficacy of radionuclide therapy in patients with disseminated neuroendocrine tumors uncontrolled by conventional therapy. J Nucl Med 2004;45:1660-1668.
116. 111In-DTPA-octreotide therapy in patients with progressive radioiodine non-responsive thyroid cancer: a pilot study. Nucl Med Commun 2004;25:683-690.
117. O'Donoghue JA, Bardies M, Wheldon TE. Relationship between tumour size and curability for targeted radionuclide therapy with beta-emitting radionuclides. J Nucl Med 1995;36:1902-1909.
118. Limouris GS, Dimitropoulos N, Kontogeorgakos D, Papanikolos G, Koutoulidis V, et al. Evaluation of the therapeutic response to In-111-DTPAoctreotide-based targeted therapy in liver metastatic neuroendocrine tumors according to CT/MRI/US findings. Cancer Biother Radiopharm 2005;20:215-217.
119. Kwekkeboom DJ, Mueller-Brand J, Paganelli G, Anthony LB, Pauwels S, et al. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med 2005;46:62S-66S.
120. Behr TM, Goldenberg DM, Becker W. Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations. Eur J Nucl Med 1998;25:201-12.
121. 111In-DTPA-octreotide. J Nucl Med 2005; 46:1696-1700.
122. 111In-DTPA]octreotide. J Nucl Med 2004;45:1168-1171.
123. 177Lu. J Nucl Med 2004;45:1260-1269.
124. Konijnenberg M, Melis M, Valkema R, Krenning E, de Jong M. Radiation dose distribution in human kidneys by octreotides in peptide receptor radionuclide therapy. J Nucl Med 2007;48:134-142.
125. 3-octreotate. J Nucl Med 2005;48:83S-91S.
126. Ginj M, Maecke HR. Synthesis of trifunctional somatostatin based derivatives for improved cellular and subcellular uptake. Tetrahedron Lett 2005;46:2821-2824.
127. Costantini DL, Hu M, Reilly RM. Peptide motifs for insertion of radiolabeled biomolecules into cells and routing to the nucleus for cancer imaging or radiotherapeutic applications. Cancer Biother Radiopharm 2008;23:3-24.
128. Ginj M, Hinni K, Tschumi S, Schultz S, Maecke HR. Trifunctional somatostatin-based derivatives designed for targeted radiotherapy using Auger electron emitters. J Nucl Med 2005;46:2097-2103.
129. 111In-labeled trastuzumab (Herceptin) modified with nuclear localization sequences (NLS): an Auger electronemitting radiotherapeutic agent for HER2/neu-amplified breast cancer. J Nucl Med 2007; 48:1357-1368.
130. 111In in human myeloid leukemia cells. J Nucl Med 2006;47:827-836.
131. 111In-anti-CD33 monoclonal antibodies modified with nuclear localizaing peptide sequences. J Nucl Med 2008;49:1546-1554.
132. Graham K, Wang Q, Boy RG, Eisenhut M, Haberkorn U, Mier W. Synthesis and evaluation of intercalating somatostatin receptor binding peptide conjugates for endoradiotherapy. J Pharm Pharmaceut Sci 2007;10:286s-297s.
133. 3-octreotate for receptor-targeted radionuclide therapy. Cancer Biother Radiopharm 2004;19:173-180.
134. Capello A, Krenning EP, Bernard BF, Breeman WAP, van Hagen MP, de Jong M. Increased cell death after therapy with an Arg-Gly-Asp-linked somatostatin analog. J Nucl Med 2004;45:1716-1720.
135. Capello A, Krenning EP, Bernard BF, Breeman WAP, Erion JL, de Jong M. Anticancer activity of targeted proapoptotic peptides. J Nucl Med 2006;47:122-129.
136. Boonstra J, Rijken P, Humbel B, Cremers F, Verkleij A, van Bergen en Henegouwen P. The epidermal growth factor. Cell Biol International 1995;19:413-430.
137. Rubin I, Yarden Y. The basic biology of HER2. Annals Oncol 2001;12 (Suppl 1): S3-S8.
138. Ciardello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 2001;7:2958-2970.
139. Battaglia F, Scambia G, Rossi S, et al. Epidermal growth factor receptor in human breast cancer: correlation with steroid hormone receptors and axillary lymph node involvement. Eur J Cancer Clin Oncol 1988;24:1685-1690.
140. Harris AL, Nicholson S, Sainsbury JRC, et al. Epidermal growth factor receptors in breast cancer: association with early relapse and death, poor response to hormones and interactions with neu. J Steroid Biochem 1989;34:123-131.
141. Klijn JGM, Berns PMJJ, Schmitz PIM, Foekens JA. The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocr Rev 1992;13:3-17.
142. 125I-Labeled human epidermal growth factor. Binding, internalization and degradation in human fibroblasts. J Cell Biol 1976;71:159-171.
143. Lo H-W, Hsu S-C, Hung M-C. EGFR signaling pathway in breast cancers: form traditional signal transduction to direct nuclear translocation. Breast Cancer Res Treat 2005;95:211-218.
144. Laduron PM. Genomic pharmacology: more intracellular sites for drug action. Biochem Pharmacol 1992;44:1233-1242.
145. Lin S-Y, Makino K, Xia W, Matin A, Wen Y, Kwong KY, et al. Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nature Cell Biol 2001; 3:802-808.
146. Lo H-W, Xia W, Wei Y, Ali-Seyed M, Huang S-F, Hung M-C. Novel prognostic value of nuclear epidermal growth factor receptor in breast cancer. Cancer Res 2005; 65:338-348.
147. Marti U, Ruchti C, Kampf J, Thomas GA, Williams ED, Peter HJ, et al. Nuclear localization of epidermal growth factor and epidermal growth factor receptors in human thyroid tissues. Thyroid 2001;11:137-145.
148. Schausberger E, Eferl R, Parzefall W, Chabikovsky M, Breit P, Wagner EF, et al. Induction of DNA synthesis in primary mouse hepatocytes is associated with nuclear pro-transforming growth factor α and erbb-1 and is independent of c-jun. Carcinogenesis 2003;24:835-841.
149. Gladhaug P, Christoffersen T. Kinetics of epidermal growth factor binding and processing in isolated intact rat hepatocytes: dynamic externalization of receptors during ligand internalization. Eur J Biochem 1987;164:267-275.
150. St. Hilaire RJ, Hradek GT, Jones AL. Hepatic sequestration and biliary secretion of epidermal growth factor: evidence for a high-capacity uptake system. Proc Natl Acad Sci USA 1983;80:3797-3801.
151. Fisher DA, Salido EC, Barajas L. Epidermal growth factor and the kidney. Ann Rev Physiol 1989;51:67-80.
152. Waltz TM, Malm C, Nishikawa BK, Wasteson A. Transforming growth factor-alpha (TGF-alpha) in human bone marrow: demonstration of TGF-alpha in erythroblasts and eosinophilic precursor cells and of epidermal growth factor receptors in blastlike cells of myelomonocytic origin. Blood 1995;85:2385-2392.
153. 111In for imaging human breast cancer. J Nucl Med 2000;41:903-911.
154. 111In-DTPA-hEGF, chemotherapeutic agents and gammaradiation on EGFR-positive breast cancer cells. Nucl Med Biol 2002;29:693-699.
155. Filmus J, Trent JM, Pollak MN, Buick RN. Epidermal growth factor receptor geneamplifiedMDA-468 breast cancer cell line and its non-amplified variants. Molec Cellular Biol 1987;7:251-257.
156. Armstrong DK, Kaufmann SH, Ottaviano YL, Furuya Y, Buckley JA, Isaacs JT, et al. Epidermal growth factor-mediated apoptosis of MDA-MB-468 human breast cancer cells. Cancer Res 1994;54:5280-523.
157. Thomas T, Balabhadrapathruni S, Gardner CR, Hong J, Faaland CA, Thomas TJ. Effects of epidermal growth factor on MDA-MB-468 breast cancer cells: alterations in polyamine biosynthesis and the expression of p21/CIP1/WAF1. J Cell Physiol 1999; 179:257-266.
158. Wang J, Chen P, Su ZF, Vallis K, Sandhu J, Cameron R, et al. Amplified delivery of indium-111 to EGFR-positive human breast cancer cells. Nucl Med Biol 2001; 28:895-902.
159. Grovdal LM, Stang E, Sorkin A, Madshus IH. Direct interaction of Cbl with pTyr 1045 of the EGF receptor (EGFR) is required to sort the EGFR to lysosomes for degradation. Exp Cell Res 2004;300:388-395.
160. Baumann M, Krause M. Targeting the epidermal growth factor receptor in radiotherapy: radiobiological mechanisms, preclinical and clinical results. Radiother and Oncol 2004;72:257-266.
161. 111In-DTPA-hEGF. J Nucl Med 2008;49:1353-1361.
162. 111In-labeled epidermal growth factor administered to athymic mice bearing epidermal growth factor receptor-positive human breast cancer xenografts. J Nucl Med 2003;44:1469-1478.
163. 111In-DTPA-human epidermal growth factor: an auger electron-emitting radiotherapeutic agent for epidermal growth factor receptor-positive breast cancer. J Nucl Med 2006;47:1023-1031.
164. 111In for radiotherapeutic applications. J Nucl Med 2004;45:701-708.
165. 111In-hEGF) in patients with metastatic EGFR-positive breast cancer. J Nucl Med 2005;46:152P.
166. 125I-labeled monoclonal antibody 425 to epidermal growth factor receptor. Cancer Res 1992;52:121-126.
167. Mattes MJ, Goldenberg DM. Therapy of human carcinoma xenografts with antibodies to EGFr and HER-2 conjugated to radionuclides emitting low-energy electrons. Eur J Nucl Med Mol Imaging 2008;35:1249-1258.
168. Michel RB, Castillo ME, Andrews PM, Mattes MJ. In vitro toxicity of A-431 carcinoma cells with antibodies to epidermal growth factor receptor and epithelial glycoprotein-1 conjugated to radionuclides emitting low-energy electrons. Clin Cancer Res 2004; 10:5957-5966.
169. Epenetos AA, Courtenay-Luck N, Pickering D, Hooker G, Durbin H, Lavender JP, et al. Antibody guided irradiation of brain glioma by arterial infusion of radioactive antibody against epidermal growth factor receptor and blood group A antigen. Br Med J 1985; 290:1463-1466.
170. Kalofonos HP, Pawlikowska TR, Hemingway A, et al. Antibody-guided diagnosis and therapy of brain gliomas using radiolabeled monoclonal antibodies against epidermal growth factor receptor and placental alkaline phosphatase. J Nucl Med 1989; 30:1636-1645.
171. 125I-labeled monoclonal antibody 425 in the treatment of high-grade brain gliomas. Int J Radiat Oncol Biol Phys 2004;58:972-975.
172. Reilly RM. The radiopharmaceutical science of monoclonal antibodies and peptides for imaging and targeted in situ radiotherapy of malignancies. In: Gad SC, editor. Handbook of Biopharmaceutical Technology. John Wiley & Sons, Toronto, 2007, pp. 987-1053.
173. Baselga J, Albanell J. Mechanism of action of anti-HER2 monoclonal antibodies. Annals Oncol 2001;12 (Suppl 1.): S35-S41.
174. Cuello M, Ettenberg AA, Clark AS, Keane MM, Posner RH, Nau MM, et al. Downregulation of the erbB-2 receptor by trastuzumab (Herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2. Cancer Res 2001;61:4892-4900.
175. Baselga J, Albanell J. Mechanism of action of anti-HER2 monoclonal antibodies. Annals Oncol 2001;12 (Suppl 1): S35-S41.
176. Xie Y, Hung M-C. Nuclear localization of p185NEU tyrosine kinase and its association with transcriptional activation. Biochem Biophys Res Commun 1994;203:1589-1598.
177. van de Vijver MJ. Assessment of the need and appropriate method for testing for the human epidermal growth factor receptor-2 (HER2). Eur J Cancer 2001;27:S11-S17.
178. Seidman AD, Fornier MN, Esteva FJ, Tan L, Kaptain S, et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 2001;19:2587-2595.
179. Baselga J. Clinical trials of Herceptin (trastuzumab). Eur J Cancer 2001;37:S18-S24.
180. Picarte M. Circumventing de novo and acquired resistance to trastuzumab: new hope for the care of ErbB2-positive breast cancer. Clin Breast Cancer 2008;8 (Suppl 3): S100-S113.
181. 111In-NLS-trastuzumab and are radiosensitized by methotrexate. J Nucl Med 2008; 49:1498-505.
182. Daghighian F, Barendswaard E, Welt S, Humm J, Scott A, Willingam MC, et al. Enhancement of radiation dose to the nucleus by vesicular internalization of iodine-125-labeled A33 monoclonal antibody. J Nucl Med 1996;37:1052-1057.
183. 131I-labeled monoclonal antibody A33 in a human colon cancer xenograft model. J Nucl Med 2001;42:1251-1256.
184. Welt S, Scott AM, Chaitanya R, Divgi R, Kemeny NE, et al. Phase I/II study of iodine-125-labeled monoclonal antibody A33 in patients with advanced colon cancer. J Clin Oncol 1996;14:1787-1797.
185. Meredith RF, Khazaeli MB, Plott WE, Spencer SA, Wheeler RH, Brady LW, et al. Initial clinical evaluation of iodine-125-labeled chimeric 17-1A for metastatic colon cancer. J Nucl Med 1995;36:2229-2233.
186. 125I-labeled monoclonal antibody 17-1A in human cancer cells. Cancer Res 1996;49:2952-2958.
187. Behr TM, Behe M, Lohr M, Sgouros G, Angerstein C, Wehrmann E, et al. Therapeutic advantages of Auger electron- over β-emitting radiometals or radioiodine when conjugated to internalizing antibodies. Eur J Nucl Med 2000;27:753-765.
188. 131I-labeled CO17-1A in a human colorectal cancer model. Int J Cancer 1998;76:738-748.
189. 125I-labelled internalized and non-internalized monoclonal antibodies in nude mice with human colon carcinoma xenografts. Nucl Med Biol 1993;20:133-144.
190. 125I-labeled anti-gp160 monoclonal antibody. Cancer Res 1988;48:2768-2773.
191. 125I-labeled 9.2.27 monoclonal antibody. Cancer Res 1985;45:5080-5087.
192. 111In) NH2]-exendin-4 is a highly efficient radiotherapeutic for glucagon-like peptide-1 receptor-targeted therapy for insulinoma. Clin Cancer Res 2007;13:3696-3705.
193. 111In)NH2] exendin-4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor targeting. J Nucl Med 2006;47:2025-2033.
194. Van de Wiele C, Dumont F, Vanden Broecke R, Oosterlinck W, Cocquyt V, et al. Technetium-99m RP527, a GRP analogue for visualisation of GRP receptor-expressing malignancies: a feasibility study. Eur J Nucl Med 2000;27:1694-1699.
195. 111In-labeled DTPA- or DOTA-bombesin analogs for receptor-targeted scintigraphy and radionuclide therapy. J Nucl Med 2002;43:1650-1656.
196. Muller C, Schubiger PA, Schibli R. Synthesis and in vitro/in vivo evaluation of novel 99mTc(CO)3-folates. Bioconjug Chem 2006;17:797-806.
197. 111In-DTPA-folate as a receptor-targeted diagnostic agent for ovarian cancer: initial clinical results. J Nucl Med 2003;44:700-707.
198. Wang S, Lee RJ, Mathias CJ, Green MA, Low PS. Synthesis, purification, and tumor cell uptake of 67Ga-deferoxamine-folate, a potential radiopharmaceutical for tumor imaging. Bioconj Chem 1996;7:56-62.
199. 111In-IGF-1(E3R) in vivo and the clonogenic survival of breast cancer cells exposed in vitro to trastuzumab (Herceptin). Nucl Med Biol 2008;35:645-653.
200. Reilly RM, Sandhu J, varez-Diez TM, Gallinger S, Kirsh J, Stern H. Problems of delivery of monoclonal antibodies. Pharmaceutical and pharmacokinetic solutions. Clin Pharmacokinet 1995;8:126-142.
201. Sastry KSR, Haydock C, Basha AM, Rao DV. Electron dosimetry for radioimmunotherapy: optimal electron energy. Radiat Prot Dosim 1985;13:249-252.
202. Hansen HJ, Ong GL, Diril H, Roche PA, Griffiths GL, Goldenberg DM, et al. Internalization and catabolism of radiolabeled antibodies to the MHC class II invariant chain by B-cell lymphomas. Biochemistry 1996;320:293.
203. Griffiths GL, Govindan SV, Sgouros G, Ong GL, Goldenberg DM, Mattes MJ. Cytotoxicity with Auger electron-emitting radionuclides delivered by antibodies. Int J Cancer 1999;81:985-992.
204. Ong GL, Elsamra SE, Goldenberg DM, Mattes MJ. Single-cell cytotoxicity with radiolabeled antibodies. Clin Cancer Res 2001;7:192-201.
205. 90Yttrium. Clin Cancer Res 2001;7:1505-1510.
206. Kurimasa A, Nagata Y, Shimizu M, Emi M, Nakamura Y, Oshimura M. A human gene that restores the DNA-repair defect in SCID mice is located on 8p11.1!q11.1. Human Genetics 1994;93:21-26.
207. Michel RB, Rosario AV, Andrews PM, Goldenberg DM, Mattes MJ. Therapy of small subcutaneous B-lymphoma xenografts with antibodies conjugated to radionuclides emitting low-energy electrons. Clin Cancer Res 2005;11:777-786.
208. Michel RB, Brechbiel MW, Mattes MJ. A comparison of 4 radionuclides conjugated to antibodies for single-cell kill. J Nucl Med 2003;44:632-640.
209. Michel RB, Mattes MJ. Intracellular accumulation of the anti-CD20 antibody 1F5 in B-lymphoma cells. Clin Cancer Res 2002;8:2701-2713.
210. 111In-conjugated antibodies. Int J Radiat Biol 2008;84:389-399.
211. Dinndorf PA, Andrews RG, Benjamin D, et al. Expression of normal myeloid-associated antigens by acute leukemia cells. Blood 1986;67:1048-1053.
212. Freeman SD, Kelm S, Barber EK, Crocker PR. Characterization of CD33 as a new member of the sialoadhesin family of cellular interaction molecules. Blood 1995;85:2005-2012.
213. Burke JM, Jurcic JG, Scheinberg DA. Radioimmunotherapy for acute leukemia. Cancer Control 2002;9:106-113.
214. Jurcic JG, Caron PC, Nikula TK, Papadopoulos EB, Finn RD, Gansow OA, et al. Radiolabeled anti-CD33 monoclonal antibody M195 for myeloid leukemias. Cancer Res 1995;55:5908s-5910s.
215. McDevitt MR, Dangshe M, Lai L, Simon J, Borchardt P, Frank KR, et al. Tumor therapy with targeted atomic nanogenerators. Science 2001;294:1537-1540.
216. Miederer M, McDevitt MR, Sgouros G, Kramer K, Cheung N-KV, Scheinberg DA. Pharmacokinetics, dosimetry, and toxicity of the targetable atomic generator, 225Ac-HuM195, in nonhuman primates. J Nucl Med 2004;45:129-137.
217. Sievers EL, Larson RA, Stadtmauer EA, Estey E, Lowenberg B, Dombret H, et al. Efficacy and safety of gemtuzumab ozagamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol 2001;19:3244-3254.
218. Sievers EL, Appelbaum FR, Spielberger RT, Forman SJ, Flowers D, Smith FO, et al. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood 1999;93:3678-3684.
219. Linenberger ML, Hong T, Flowers D, Sievers EL, Gooley TA, Bennett JM, et al. Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin. Blood 2001;98:988-994.
220. Feldman EJ, Brandwein J, Stone R, Kalaycio M, Moore J, et al. Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. J Clin Oncol 2005;23:4110-4116.
221. Caron PC, Co MS, Bull MK, Avdalovic NM, Queen C, Scheinberg DA. Biological and immunological features of humanized M195 (anti-CD33) for the therapy of acute myelogenous leukemia. Cancer Res 1992;52:6761-6762.
222. 125I-labeled monoclonal antibody T101 in human malignant T cell lines. Blood 1986;67:429-435.
223. 123I-ITdU-mediated nanoirradiation of DNA efficiently induces cell kill in HL-60 leukemia cells and in doxorubicin-, β-, or χ-radiation-resistant cell lines. J Nucl Med 2007;48:1000-1007.
224. Weisburg JH. Multidrug resistance in acute myeloid leukemia: potential new therapeutics. J Nucl Med 2008;49:1405-1406.
225. 125I]iodo-17β-estradiol. J Cancer Res Clin Oncol 1993;119:207-214.
226. DeSombre ER, Mease RC, Hughes A, Harper PV, DeJesus OT, Friedman AM. Bromine-80m-labeled estrogens: Auger electron-emitting, estrogen receptor-directed ligands with potential for therapy of estrogen receptor-positive cancers. Cancer Res 1988;48:899-906.
227. DeSombre ER, Hughes A, Hanson RN, Kearney T. Therapy of estrogen receptor-positive micrometastases in the peritoneal cavity with Auger electron-emitting estrogens. Acta Oncol 2000;39:659-666.
228. DeSombre ER, Shaffii B, Hanson RN, Kuivanen PC, Hughes A. Estrogen receptordirected radiotoxicity with Auger electrons: specificity and mean lethal dose. Cancer Res 1992;52:5752-5758.
229. Gaze MN, Huxham IM, Mairs RJ, Barrett A. Intracellular localization of metaiodobenzylguanidine in human neuroblastoma cells by electron spectroscopic imaging. Int J Cancer 1991;47:875-880.
230. Hoefnagel CA, Smets LA, Voute PA, de Kraku J. Iodine-125-MIBG therapy for neuroblastoma. J Nucl Med 1992;32:361-362.
231. 125I]metaiodobenzylguanidine. Int J Radiat Oncol Biol Phys 1998;41:425-432.
232. 125I]metaiodobenzylguanidine therapy in macroscopic and microscopic tumors: a comparative study in SK-N-SH human neuroblastoma and PC12 rat pheochromocytoma xenografts. Int J Cancer 2000;90:312-325.
233. Sisson JC, Hutchinson RJ, Shapiro B, Zasadny KR, Normolle DP, Wieland DM, et al. Iodine-125-MIBG to treat neuroblastoma: preliminary report. J Nucl Med 1990;31:1479-1485.
234. 125I-MIBG. Am J Clin Oncol 1996;19:144-148.
235. 125I-labeled daunorubicin derivative for radionuclide-based cancer therapy. Nucl Med Biol 2006;33:773-783.
236. Haefliger P, Agorastos N, Renard A, Giambonini-Brugnoli G, Marty C, Alberto R. Cell uptake and radiotoxicity studies of an nuclear localization signal peptide-intercalator conjugate labeled with [99mTc(CO)3] +. Bioconjug Chem 2005;16:582-587.
237. Häfliger P, Agorastos N, Spingler B, Georgiev O, Viola G, Alberto R. Induction of DNA-doule-strand breaks by Auger electrons from 99mTc complexes with DNA-binding ligands. ChemBioChem 2005;6:414-421.
238. Freiss G, Prebois C, Vignon F. Control of breast cancer growth by steroids and growth factors: interactions and mechanisms. Breast Cancer Res Treat 1993;27:57-68.
239. Nardulli AM, Katzenellenbogen BS. Dynamics of estrogen receptor turnover in uterine cells in vitro and in uteri in vivo. Endocrinol 1986;119:2038-2046.
240. Sainsbury JRC, Farndon JR, Sherbet GV, Harris AL. Epidermal growth factor receptors and oestrogen receptors in human breast cancer. Lancet 1985;1(8425): 364-366.
241. Chrysogelos SA, Yarden RI, Lauber AH, Murphy JM. Mechanisms of EGF receptor regulation in breast cancer cells. Breast Cancer Res Treat 1994;31:227-236.
242. King RJB. Progression from steroid sensitive to insensitive state in breast tumours. Cancer Surv 1992;14:131-146.
243. 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma. J Clin Oncol 1998;16:229-236.
244. 131I MIBG therapy in neuroblastoma: mechanisms, rationale, and current status. Med Pediatr Oncol 1999;32:427-431.
245. Cunningham SH, Mairs RJ, Wheldon TE, Welsh PC, Vaidyanathan G, Zalutsky MR. Toxicity to neuroblastoma cells and spheroids of benzylguanidine conjugated to radionuclides with short-range emissions. Br J Cancer 1998;77:2061-2068.
246. 123I]iodobenzylguanidine is selectively radiotoxic to neuroblastoma cells at concentrations that spare cells of hematopoietic lineage. Nucl Med Commun 2004;25:1125-1130.
247. Kiyomiya K, Matsuo S, Kurebe M. Mechanism of specific nuclear transport of adriamycin: the mode of nuclear translocation of adriamycin-proteosome complex. Cancer Res 2001;61:2467-2471.